Services: Células madre y exosomas

What It Is

A stem cell can copy itself and become other kinds of cell, the raw material the body uses to repair tissue. The word covers two very different things. The first is a narrow, approved field of medicine. Blood-forming stem-cell transplants have cured blood cancers for more than 50 years, and cultured limbal stem cells can rebuild a cornea destroyed by a burn. The second, a consumer marketplace, sells injections outside that approved field.

Stem Cells, Exosomes, and What the Clinics Inject

1Flexible cells versus limited ones

Embryonic and certain lab-reprogrammed cells can become almost any tissue. The adult cells used in most clinics, mainly mesenchymal stromal cells taken from body fat or bone marrow, are far more limited in what they can turn into.

2What the clinics inject

Direct-to-consumer clinics draw these cells from a patient, or use cells from donated cord blood. They inject them into a joint, a vein, or, in some cases, the eye. The cells are frequently not characterized or standardized, so what is in the syringe varies.

3Where exosomes fit

Cells release exosomes, tiny membrane vesicles, to signal to one another. Products marketed as exosome therapy are cell-free preparations promoted as the next step beyond stem cells.

How It Works

The picture sold to patients is simple. Injected cells travel to the damage, engraft, and become the tissue a patient hopes to regrow: cartilage, nerve, or retina. For the mesenchymal stromal cells most clinics use, that is largely not what happens. These cells rarely engraft or turn into new tissue after an injection. Where they do act, the effect is paracrine and short-lived. For a brief window they release signaling molecules that calm inflammation, then the body clears them. Arnold Caplan, who named the field, has argued the cells were misnamed, because they signal to nearby tissue instead of building it.

A few of these treatments are settled, curative medicine. Most are sold before any trial has shown they work.

What Changed

For decades, stem-cell medicine meant transplant and a short list of established procedures. Then a consumer market formed beside it. A 2016 survey counted hundreds of United States businesses marketing stem-cell interventions directly to consumers for a wide range of conditions. Later reviews describe a sector that kept expanding and added exosome offerings.

Where The Research Stands

Two of these uses are settled, curative medicine. The others rest on far less: small trials, or none at all.

The Research & Studies

Everything here is based on the research we have collected and checked, sorted into groups and ordered with the strongest evidence first. Click any claim to open the studies behind it.

Cancer Risk And Outcome

El trasplante de médula ósea y células madre de sangre cura los cánceres de la sangre, atención estándar durante más de cincuenta añosStrong

In plain terms

El trasplante de médula ósea y células madre de sangre es una cura para cánceres de la sangre como la leucemia, y ha sido atención médica estándar durante décadas.

In detail

El trasplante de células madre hematopoyéticas, que usa células madre formadoras de sangre procedentes de la médula ósea, la sangre circulante o la sangre de cordón para reconstituir el sistema sanguíneo e inmunitario, es una terapia curativa establecida para la leucemia, el linfoma y otros trastornos de la sangre y la médula, con más de cincuenta años de uso clínico. Se trata de un tratamiento hospitalario exigente con riesgos propios significativos, y es un uso específico aprobado que no se extiende a las inyecciones para el envejecimiento, las articulaciones y las enfermedades crónicas comercializadas por clínicas directas al consumidor.

The study · 1

Copelan, Hematopoietic stem-cell transplantation · N Engl J Med 2006;354(17):1813-1826

Vision

Las células madre limbales cultivadas restauraron una superficie corneal transparente en el 76.6 % de los ojos en 112 pacientes con quemadurasModerate

In plain terms

Las células madre tomadas del borde del propio ojo del paciente, cultivadas en el laboratorio y trasplantadas de vuelta, reconstruyeron de forma permanente una superficie corneal transparente en aproximadamente tres cuartas partes de los ojos cegados por quemaduras.

In detail

En 112 pacientes con córneas destruidas principalmente por quemaduras químicas o térmicas, el tratamiento con células madre limbales autólogas cultivadas restauró un epitelio corneal permanente, transparente y autorrenovable en el 76.6 % de los ojos, con éxitos estables durante el seguimiento a largo plazo y fracasos que ocurrieron dentro del primer año. Se trata de un tratamiento específico para el déficit de células madre limbales relacionado con quemaduras, administrado en un entorno especializado, no evidencia para las inyecciones regenerativas generales vendidas por clínicas, y fue una serie de casos no controlada, no un ensayo aleatorizado.

The study · 1

Rama et al., Limbal stem-cell therapy and long-term corneal regeneration · N Engl J Med 2010;363(2):147-155

How it works

Injected mesenchymal cells act by brief paracrine signaling, not by becoming new tissueModerate · mixed

In plain terms

The stem cells clinics usually inject do not settle in and turn into new cartilage or nerve. At most they release signaling chemicals for a short time and are then cleared, which is not the tissue rebuilding the marketing suggests.

In detail

Mesenchymal stromal cells, the cells most clinics inject, rarely engraft or differentiate into new tissue after injection; where they act, their effect is chiefly paracrine and transient, releasing signaling molecules that modulate inflammation before the cells are cleared, which is a different action from the tissue replacement implied by their marketing. This describes the dominant understanding of adult mesenchymal stromal cells and does not extend to embryonic or reprogrammed cells, and the strength and duration of the signaling effect vary by cell source and preparation.

The study · 1

Caplan, Mesenchymal Stem Cells: Time to Change the Name! · Stem Cells Transl Med 2017;6(6):1445-1451

Joint And Arthritis Pain

Stem-cell knee injections eased pain and function modestly in four small trials of 138 patientsPreliminary

In plain terms

For arthritic knees, four small randomized trials of 138 patients pooled together show stem-cell injections modestly improve pain and function, but the studies are inconsistent and have not been shown to beat cheaper standard treatments.

In detail

A meta-analysis pooling four randomized controlled trials of adipose-derived mesenchymal stromal cell injection for knee osteoarthritis, totaling 138 patients, found improvement in pain and function at 12-month follow-up, but from small trials that varied widely in cell source and preparation and had short follow-up, and without demonstrating superiority over cheaper established options. The trials are small, heterogeneous in how cells are sourced and prepared, and short in follow-up, and none establish that these injections outperform physical therapy or standard injections that cost a fraction as much.

The study · 1

Issa et al., The role of adipose-derived mesenchymal stem cells in knee osteoarthritis: a meta-analysis of randomized controlled trials · Ther Adv Musculoskelet Dis 2022;14:1759720X221146005

The Established Uses

Hematopoietic stem-cell transplant rebuilds a patient's blood and immune system from blood-forming stem cells taken from bone marrow, circulating blood, or cord blood. It is standard curative care for leukemia, lymphoma, and other blood disorders. Cultured limbal stem cells are the other settled use. Across 112 patients whose corneas were destroyed mostly by chemical or thermal burns, cultured limbal cells rebuilt a permanent, self-renewing corneal surface in 76.6% of eyes. Those successes held over long follow-up. A small set of other cell products also carries regulatory approval for defined conditions. Each of these uses is precise, tested, and delivered under regulatory oversight.

The Direct-to-Consumer Market

Most of these clinic products are investigational: unapproved for the conditions advertised, with a clinical trial as the expected next step. Many are sold as finished treatments instead. Clinics market them as broadly effective and blame slow approval for the missing evidence. The same product is sold for four unrelated conditions, aging, joints, autism, and multiple sclerosis, and no completed trial supports any of them.

The Documented Harms

Three harms are on record, each from injectable biological products sold outside the testing that approved treatments carry. In one case series, a clinic injected fat-derived cells into both eyes of three patients in a single session for macular degeneration, and all three were blinded. A product made from donated cord blood carried bacteria and caused bloodstream infections in the patients who received it. Cash-paid clinics have also triggered dangerous joint infections.

The Orthopedic Evidence

The knee is where clinic claims are strongest and most common. The cells clinics inject have been tested for knee osteoarthritis in several small randomized trials. A meta-analysis of those trials found a real improvement in pain and function. The signal is limited: the trials are small, they vary widely in how the cells are sourced and prepared, and follow-up is short. They have not shown durable superiority over standard options such as physical therapy or standard injections in adequately powered head-to-head trials. For a knee, the benefit is modest and preliminary. Physical therapy and standard care stay the tested option.

Exosomes

Exosomes reached clinics last, and scientifically they are the most interesting part of the field. The rationale follows from the cell biology. If a mesenchymal cell mostly works by sending chemical messages, those messages, packaged in exosomes, might be delivered on their own. As cell-free preparations of signaling vesicles, they are a genuine and promising research subject. Scientists who study extracellular vesicles have published position papers calling exosome medicines premature and unconfirmed. The block is the absence of a standardized way to define a product or measure its dose. No exosome product is approved for the anti-aging and regenerative uses clinics advertise. Preparations sold as exosome therapy raise the same contamination concerns as the cell products that caused infections.

Go Deeper

• The biology of aging: the drivers behind the renewal that stem-cell and exosome clinics promise to restore.
• Rapamycin: another field where a few approved drugs sit beside a large off-label market, and how to keep the two apart.
• Senolytics: a different anti-aging approach, aimed at clearing worn-out cells instead of adding new ones.
• Peptides: a neighboring market of injectable products sold ahead of the trials, with the same approval gap.

The Chinese Medicine View

Stem cells and exosomes come from modern cell biology, isolated and named in the 20th and 21st centuries; no classical Chinese text describes them, and no traditional formula contains them.

Chinese medicine centers renewal and constitutional reserve on the Kidney and its store of Jing, the essence. The Kidney holds Jing as a deep reserve, present at birth and drawn down across a lifetime. The classics describe its decline in signs close to what modern medicine calls aging.

Building the body up, what the tradition calls tonifying, is warranted only when there is a true deficiency and the person can assimilate what is given. The classics warn that over-treating a depleted body weakens it further.

Cautions

Everything to be aware of is here, in one place. This practice suits most healthy people; a few situations call for real care.

Solo unos pocos productos celulares están aprobados; la mayoría de los regenerativos comercializados siguen siendo de investigación

Según el marco regulatorio para los productos basados en células, solo un pequeño número de terapias celulares están aprobadas para afecciones definidas, mientras que la mayoría de los productos comercializados para usos regenerativos y antienvejecimiento son de investigación y se espera que se estudien en ensayos clínicos, no que se vendan como tratamientos. La línea entre un producto aprobado y uno de investigación es un juicio regulatorio que sigue siendo disputado y que se aplica de forma desigual, por lo que que un producto esté en el mercado no es lo mismo que esté aprobado.Marks and Gottlieb, Balancing Safety and Innovation for Cell-Based Regenerative Medicine

Cientos de clínicas de EE. UU. venden inyecciones de células madre y exosomas para usos que los productos no están aprobados para tratar

Una encuesta de 2016 en Estados Unidos identificó a cientos de negocios que comercializaban intervenciones con células madre directamente a los consumidores para una amplia gama de afecciones, y revisiones posteriores describen un sector que ha seguido creciendo y añadiendo ofertas de exosomas, en gran parte al margen de las afecciones para las que los productos están aprobados. Los recuentos provienen de la autopromoción de las clínicas y su presencia web, por lo que el número real de negocios y lo que cada uno ofrece realmente podría estar subestimado o mal representado, pero la escala del mercado no está en duda.Turner and Knoepfler, Selling Stem Cells in the USA: Assessing the Direct-to-Consumer IndustryBrinsfield et al., The evolution and ongoing challenge of unproven cell-based interventions

Tres mujeres pasaron de una visión casi normal a la ceguera después de que se les inyectaran células derivadas de grasa en ambos ojos

Tres pacientes sufrieron una pérdida de visión bilateral grave después de que una clínica les inyectara células madre autólogas derivadas de tejido adiposo en ambos ojos para la degeneración macular relacionada con la edad; la agudeza visual cayó de un rango previo a la inyección de 20/30 a 20/200 hasta un rango de 20/200 a ausencia de percepción de luz un año después, con complicaciones que incluyeron hipertensión ocular, retinopatía hemorrágica y desprendimiento de retina. Se trata de una serie de casos de tres pacientes, por lo que establece que puede ocurrir un daño grave, no una tasa, y la inyección se realizó en ambos ojos el mismo día, lo que eliminó cualquier ojo sano de reserva.Kuriyan et al., Vision Loss after Intravitreal Injection of Autologous Stem Cells for AMD

Infecciones del torrente sanguíneo rastreadas hasta un producto de sangre de cordón contaminado bacterianamente

Los pacientes que recibieron un producto derivado de sangre de cordón umbilical para usos distintos de la reconstitución sanguínea o inmunitaria desarrollaron infecciones del torrente sanguíneo que la investigación de salud pública rastreó hasta la contaminación bacteriana del propio producto. Se trató de una investigación de brote de un producto contaminado específico, no un estudio de una tasa en todas las clínicas, y refleja el riesgo de contaminación de productos fabricados y manipulados fuera de la fabricación aprobada.Perkins et al., Notes from the Field: Infections After Receipt of Bacterially Contaminated Umbilical Cord Blood-Derived Stem Cell Products

Infecciones articulares graves que requirieron cirugía tras inyecciones intraarticulares en clínicas de pago en efectivo

Se han notificado casos de infección articular grave que requirió tratamiento quirúrgico después de que los pacientes recibieran inyecciones intraarticulares de células madre en clínicas de pago en efectivo por molestias articulares. These are individual case reports, not a measured infection rate, but they document that injected products from unregulated clinics can introduce joint infection.Taliaferro et al., Cash-Based Stem-Cell Clinics: The Modern Day Snake Oil Salesman? A Report of Two Cases

No exosome product is approved, and no standard yet defines a product dose or potency

Position papers from extracellular-vesicle researchers describe the development of exosome-based therapeutics as early and unfinished, held back by the lack of standardized methods to define product identity, quantify dose and confirm potency, and no exosome product is approved for the regenerative and anti-aging uses that clinics advertise. Exosome therapeutics are a legitimate and active research field, so this describes their early developmental and regulatory status, not a verdict on their eventual potential.Lener et al., Applying extracellular vesicles based therapeutics in clinical trials: an ISEV position paperSilva et al., Development of extracellular vesicle-based medicinal products: a position paper

Stem-cell tourism has caused serious complications, including neurological, and strips away safeguards

Critical reviews of international stem-cell tourism document serious complications in patients who travel abroad for unregulated stem-cell interventions, including neurological complications, and note the absence of the manufacturing oversight, consent standards and follow-up that regulated care provides. The evidence is drawn from reviews and reported cases, not systematic outcome tracking, because these interventions are delivered outside the systems that would record complications, which itself is part of the risk.Lyons et al., International stem cell tourism: a critical literature review and evidence-based recommendationsJulian et al., The Growing Reality of the Neurological Complications of Global Stem Cell Tourism

Approval here is narrow

Hematopoietic transplant and limbal cell therapy are established care. The injections sold for anti-aging, orthopedic, and chronic-disease uses are not approved for those uses.

Injections near the eye can blind

An injection into or around the eye carries a risk of severe, permanent vision loss, and the eye cannot regrow tissue it loses.

Contaminated products cause infections

Products made and handled outside approved manufacturing can be contaminated. An injected infection can be limb- or life-threatening.

Treatment abroad removes the safeguards

Traveling abroad for stem-cell treatment can mean an injection with none of the manufacturing oversight, consent standards, or follow-up of regulated care. Reviews document serious complications, including neurological ones, in returning patients. A treatment you can only get abroad is usually unavailable at home because it has not passed the required testing.

Start slow, be smart, read the research, and consult a professional if you have any concerns. This is here to inform your choice, not make it for you.

Common Questions

Which of these are approved treatments?

Hematopoietic transplant for blood cancers and cultured limbal stem cells for a burned cornea are approved and regulated. The injections marketed for aging and worn joints are not. The dividing line is regulatory approval and evidence from a finished trial.

Can stem cells reverse aging or regrow a joint?

No completed trial shows either claim. Both come from marketing, and no results in patients back them.

Why does it cost thousands of dollars if it is not approved?

Products sold outside the approval framework are cash services; insurance and regulators cover only licensed medicines. A high price and a professional setting can look like proof of value on their own.

Is it safe to get an injection at a clinic?

The known safety problems trace to products made and injected outside regulated manufacturing. These products skip the FDA oversight that approved treatments clear, and contamination is the real risk.